The effects of the "vestibular sedative" drug, Flunarizine upon the vestibular and oculomotor systems
- PMID: 6604134
- PMCID: PMC1027524
- DOI: 10.1136/jnnp.46.8.716
The effects of the "vestibular sedative" drug, Flunarizine upon the vestibular and oculomotor systems
Abstract
The effects of the "vestibular sedative" drug Flunarizine upon the oculomotor functions of pursuit and voluntary saccades and upon the vestibular response (to rotational stimuli) were assessed in twenty volunteer subjects. The study was then extended to three patients with chronic imbalance of central origin who had reported a beneficial symptomatic response to the drug. Three of the volunteer subjects were found to have a directional preponderance (presumed to arise from peripheral dysfunction). In the remaining seventeen normal subjects Flunarizine was found to reduce the amplitudes of fast phases of vestibular nystagmus. The directional preponderance in the other three subjects was redressed through production of fast phases which were of lower and more uniform amplitude. In the patients, in addition to a reduction in fast phase amplitude, there was a reduction or abolition of after nystagmus. In no case was any reduction in slow phase velocity observed. Pursuit and voluntary saccades were unaffected by the drug. It was concluded, on the basis that the fast phases of nystagmus are centrally generated, that Flunarizine has a central action rather than a depressant effect upon the vestibular end organ. In view of known oculomotor physiology and pharmacology it is proposed that vestibular sedatives act by depression of Type II vestibular neurons, and modification of the functional relationships between the vestibular nuclei, the perihypoglossal nuclei and the flocculus of the cerebellum. A trial of vestibular active drug is indicated particularly in patients in whom asymmetry of the vestibular response and/or abnormal after nystagmus is demonstrated.
Similar articles
-
Flunarizine and cinnarizine as vestibular depressants. A statistical study.ORL J Otorhinolaryngol Relat Spec. 1978;40(2):92-100. doi: 10.1159/000275391. ORL J Otorhinolaryngol Relat Spec. 1978. PMID: 311458 Clinical Trial.
-
Influence of flunarizine on the altered electronystagmographic (ENG) recordings in migraine.Cephalalgia. 1985 May;5 Suppl 2:173-5. doi: 10.1177/03331024850050S233. Cephalalgia. 1985. PMID: 4016930 Clinical Trial.
-
Pharmacological improvement of vestibular plasticity. Effects of a Ca2+-antagonist agent.Pharmacol Res Commun. 1984 Dec;16(12):1161-73. doi: 10.1016/s0031-6989(84)80081-8. Pharmacol Res Commun. 1984. PMID: 6335255
-
Flunarizine in the treatment of vertigo.J Laryngol Otol. 1983 Aug;97(8):697-704. doi: 10.1017/s0022215100094858. J Laryngol Otol. 1983. PMID: 6350513 Review.
-
[Agents to improve cerebrovascular circulation and cerebral metabolism--flunarizine].Nihon Rinsho. 1985 Feb;43(2):402-5. Nihon Rinsho. 1985. PMID: 3889415 Review. Japanese. No abstract available.
Cited by
-
Slow channel inhibitor effects on brain function: tolerance to severe hypoxia in the rat.Br J Pharmacol. 1988 Nov;95(3):903-13. doi: 10.1111/j.1476-5381.1988.tb11720.x. Br J Pharmacol. 1988. PMID: 3264735 Free PMC article.
-
Antivertigo medications and drug-induced vertigo. A pharmacological review.Drugs. 1995 Nov;50(5):777-91. doi: 10.2165/00003495-199550050-00002. Drugs. 1995. PMID: 8586026 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources